Pinnbrook Capital Management LP Purchases New Holdings in Merck & Co., Inc. $MRK

Pinnbrook Capital Management LP purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 11,925 shares of the company’s stock, valued at approximately $1,001,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Darwin Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after purchasing an additional 216 shares during the last quarter. Kilter Group LLC purchased a new position in shares of Merck & Co., Inc. in the 2nd quarter worth about $27,000. Bare Financial Services Inc boosted its holdings in shares of Merck & Co., Inc. by 51.9% in the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock worth $29,000 after buying an additional 125 shares during the last quarter. Barnes Dennig Private Wealth Management LLC grew its position in Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after buying an additional 266 shares during the period. Finally, Evolution Wealth Management Inc. bought a new position in Merck & Co., Inc. during the second quarter valued at about $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.3%

Shares of MRK opened at $115.61 on Friday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The business has a 50-day moving average of $115.26 and a 200 day moving average of $99.58. The firm has a market cap of $285.84 billion, a P/E ratio of 15.88, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Insider Activity at Merck & Co., Inc.

In related news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the completion of the transaction, the insider directly owned 21,197 shares of the company’s stock, valued at approximately $2,583,278.39. This trade represents a 41.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the completion of the transaction, the chief marketing officer owned 70,615 shares of the company’s stock, valued at $8,361,522.15. This represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 320,176 shares of company stock worth $38,281,735 in the last ninety days. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on MRK. TD Cowen raised their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a report on Tuesday, January 20th. Royal Bank Of Canada assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, February 25th. They set an “outperform” rating and a $142.00 target price for the company. Scotiabank raised their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research note on Thursday, December 4th. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. Finally, Bank of America lifted their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $126.81.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.